Prolonged Efficacy of Bifidobacterium Lactis in the Treatment of Functional Dyspepsia: A Randomized, Positive-Drug and Placebo-Controlled Clinical Trial
Qi Zhang,Guang Li,Wen Zhao,Limian Zhou,Xiaoxu Zhang,Jingjing He,Peng An,Yinghua Liu,Chengying Zhang,Yong Zhang,Simin Liu,Wei-Hsien Liu,Fudong Liu,Yixuan Li,Wenjian Jiang,Xifan Wang,Xiaoyu Wang,Qingyu Wang,Bing Fang,Meng Guo,Yuyang Zhao,Yimei Ren,Xiaokang Niu,Dongjie Li,Chao Zhang,Shaoqi Shi,Ran Wang,Xinjuan Liu,Wei-Lian Hung,Fazheng Ren
DOI: https://doi.org/10.2139/ssrn.4307628
2022-01-01
SSRN Electronic Journal
Abstract:Background: Current treatment for functional dyspepsia (FD) has limited and unsustainable efficacy. Probiotics have the potential to alleviate FD; However, the underlying mechanism remains unclear. This study aimed to evaluate the effect and mechanism of probiotics in alleviating FD.Methods: A randomized, positive-drug, placebo-controlled clinical trial was conducted at Beijing Chaoyang Hospital, Capital Medical University; Patients with FD (18-60 years, defined according to the Rome IV criteria) were randomly divided into four groups [placebo, positive control (proton pump inhibitors, PPIs), Bifidobacterium lactis BL-99_low and BL-99_high doses] to receive 8-week treatment, 2-week follow-up and 6-week questionnaire survey. The primary outcome was the clinical response rate, defined as a decrease in postprandial distress syndrome (PDS)+epigastric pain syndrome (EPS) scores greater than 0.5. Moreover, FD-related serum indicators including pepsinogen (PG) and gastrin17 (G17) were tested using ELISA kit. Metagenomics, un-target and target metabolomics technology were performed to assess the faecal microbiota and metabolites. This study was registered at Chictr.org.cn (ChiCTR2000041430).Findings: From 26 December 2020 to 10 February 2021, a total of 200 FD patients [51 (25.5%) men, 51.43 years (50.12-52.74)] were assigned. The primary outcome for BL-99_high [43 (95.6%) of 45] group was significantly higher than that for placebo [28 (62.2%) of 45; risk ratio (RR) vs BL-99_high, 13.05 (95% CI 2.80-60.92), P=0.001], BL-99_low [36 (76.6%) of 47; RR 6.57 (95% CI 1.37-31.59), P=0.019]or positive control group [34 (70.8%) of 48; RR 8.85 (95% CI 1.88-41.64), P=0.006] after 8-week treatment. In particular, The clinical response rate for BL-99_high group [40 (88.9%) of 45] was still significantly higher than that for placebo [30 (66.7%) of 45; RR 4.00 (95% CI 1.31-12.23), P=0.015] and positive control group [32 (66.7%) of 48; RR 4.00 (95% CI 1.32-12.10), P=0.014] after 2-week follow-up. High dose BL-99 also increased serum PGI, and G17 levels, and decreased PG II levels compared to the placebo and positive control group after an 8-week treatment, and this effect lasted until the end of the follow-up. Further metagenomic and metabolomics studies found that PPIs significantly decreased the gut microbiota diversity, induced the cluster of Escherichia enterotype and decreased butyrate contents. Interestingly, the colonisation of BL-99 converted the gut microbiota enterotype of FD patients from Bacteroidetes (Alistipes finegoldii, Alistipes shahii) to Firmicutesc (Roseburia intestinalis, Roseburia inulinivorans) and Escherichia enterotype was not clustered after 8-week treatment, which activates carbohydrate esterase activity, and increases faecal and serum butyrate levels.Interpretation: BL-99 sustainably alleviated FD symptoms by altering the taxonomic composition and functional potential of the FD microbiome, which increased faecal and serum butyrate, and regulated the release of PGI, PGII and G17.Trial Registration Details: This study was registered at Chictr.org.cn (ChiCTR2000041430).Funding Information: This work was financially supported by National Key R&D Program of China (grant number 2021YFD1600204), The 111 project from the Education Ministry of China (No. B18053), and Key project of multidisciplinary Clinical Research Innovation Team of Beijing Chaoyang Hospital Affiliated to Capital Medical University (CYDXK202207)Declaration of Interests: All authors declare no competing interests.Ethics Approval Statement: The trial conformed to the provisions of the Declaration of Helsinki and was approved by the Ethics Committee of CCMU (NO.2020-ke-497). All participants provided written informed consent before inclusion.